Cargando…

Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib

Ruxolitinib is a selective JAK1/2 inhibitor that is widely used for the treatment of myeloproliferative neoplasms (MPNs), including myelofibrosis and polycythemia vera (PV). Despite its clinical efficacy for MPNs, ruxolitinib possesses immunosuppressive properties that potentially increase the risks...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakiyama, Emiko, Chinen, Yoshiaki, Tsukamoto, Taku, Takimoto-Shimomura, Tomoko, Kuwahara-Ota, Saeko, Matsumura-Kimoto, Yayoi, Shimura, Yuji, Kobayashi, Tsutomu, Horiike, Shigeo, Kuroda, Junya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152536/
https://www.ncbi.nlm.nih.gov/pubmed/32308443
http://dx.doi.org/10.2147/IDR.S249030
_version_ 1783521500809134080
author Sakiyama, Emiko
Chinen, Yoshiaki
Tsukamoto, Taku
Takimoto-Shimomura, Tomoko
Kuwahara-Ota, Saeko
Matsumura-Kimoto, Yayoi
Shimura, Yuji
Kobayashi, Tsutomu
Horiike, Shigeo
Kuroda, Junya
author_facet Sakiyama, Emiko
Chinen, Yoshiaki
Tsukamoto, Taku
Takimoto-Shimomura, Tomoko
Kuwahara-Ota, Saeko
Matsumura-Kimoto, Yayoi
Shimura, Yuji
Kobayashi, Tsutomu
Horiike, Shigeo
Kuroda, Junya
author_sort Sakiyama, Emiko
collection PubMed
description Ruxolitinib is a selective JAK1/2 inhibitor that is widely used for the treatment of myeloproliferative neoplasms (MPNs), including myelofibrosis and polycythemia vera (PV). Despite its clinical efficacy for MPNs, ruxolitinib possesses immunosuppressive properties that potentially increase the risks for opportunistic infection, such as mycobacterium tuberculosis (MTB) infection, and reactivation of occult viral infection. Herein, we report the case of a 76-year-old male with PV who developed tuberculosis peritonitis under ruxolitinib therapy for 28 weeks. While previous studies and case reports have suggested an increased risk of MTB infection of various organs during ruxolitinib treatment of MPNs, this case is apparently the first of tuberculosis peritonitis in a patient with MPN treated with ruxolitinib. A review of previous case reports suggests the need for careful observation for MTB from the relatively early phase of ruxolitinib treatment, given that the median duration from the start of ruxolitinib treatment to the emergence of MTB was 20 weeks (range: 3–88 weeks). Clinicians should consider tuberculosis peritonitis as a differential diagnosis when patients with MPN treated with ruxolitinib develop infectious abdominal symptoms.
format Online
Article
Text
id pubmed-7152536
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-71525362020-04-17 Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib Sakiyama, Emiko Chinen, Yoshiaki Tsukamoto, Taku Takimoto-Shimomura, Tomoko Kuwahara-Ota, Saeko Matsumura-Kimoto, Yayoi Shimura, Yuji Kobayashi, Tsutomu Horiike, Shigeo Kuroda, Junya Infect Drug Resist Case Report Ruxolitinib is a selective JAK1/2 inhibitor that is widely used for the treatment of myeloproliferative neoplasms (MPNs), including myelofibrosis and polycythemia vera (PV). Despite its clinical efficacy for MPNs, ruxolitinib possesses immunosuppressive properties that potentially increase the risks for opportunistic infection, such as mycobacterium tuberculosis (MTB) infection, and reactivation of occult viral infection. Herein, we report the case of a 76-year-old male with PV who developed tuberculosis peritonitis under ruxolitinib therapy for 28 weeks. While previous studies and case reports have suggested an increased risk of MTB infection of various organs during ruxolitinib treatment of MPNs, this case is apparently the first of tuberculosis peritonitis in a patient with MPN treated with ruxolitinib. A review of previous case reports suggests the need for careful observation for MTB from the relatively early phase of ruxolitinib treatment, given that the median duration from the start of ruxolitinib treatment to the emergence of MTB was 20 weeks (range: 3–88 weeks). Clinicians should consider tuberculosis peritonitis as a differential diagnosis when patients with MPN treated with ruxolitinib develop infectious abdominal symptoms. Dove 2020-04-08 /pmc/articles/PMC7152536/ /pubmed/32308443 http://dx.doi.org/10.2147/IDR.S249030 Text en © 2020 Sakiyama et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Sakiyama, Emiko
Chinen, Yoshiaki
Tsukamoto, Taku
Takimoto-Shimomura, Tomoko
Kuwahara-Ota, Saeko
Matsumura-Kimoto, Yayoi
Shimura, Yuji
Kobayashi, Tsutomu
Horiike, Shigeo
Kuroda, Junya
Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib
title Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib
title_full Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib
title_fullStr Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib
title_full_unstemmed Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib
title_short Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib
title_sort tuberculosis peritonitis during treatment of polycythemia vera with ruxolitinib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152536/
https://www.ncbi.nlm.nih.gov/pubmed/32308443
http://dx.doi.org/10.2147/IDR.S249030
work_keys_str_mv AT sakiyamaemiko tuberculosisperitonitisduringtreatmentofpolycythemiaverawithruxolitinib
AT chinenyoshiaki tuberculosisperitonitisduringtreatmentofpolycythemiaverawithruxolitinib
AT tsukamototaku tuberculosisperitonitisduringtreatmentofpolycythemiaverawithruxolitinib
AT takimotoshimomuratomoko tuberculosisperitonitisduringtreatmentofpolycythemiaverawithruxolitinib
AT kuwaharaotasaeko tuberculosisperitonitisduringtreatmentofpolycythemiaverawithruxolitinib
AT matsumurakimotoyayoi tuberculosisperitonitisduringtreatmentofpolycythemiaverawithruxolitinib
AT shimurayuji tuberculosisperitonitisduringtreatmentofpolycythemiaverawithruxolitinib
AT kobayashitsutomu tuberculosisperitonitisduringtreatmentofpolycythemiaverawithruxolitinib
AT horiikeshigeo tuberculosisperitonitisduringtreatmentofpolycythemiaverawithruxolitinib
AT kurodajunya tuberculosisperitonitisduringtreatmentofpolycythemiaverawithruxolitinib